eBC and mBC Treatment | KISQALI® (ribociclib)
KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: in combination with an aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back.
Kisqali: Uses, Dosage, Side Effects, Warnings - Drugs.com
5 days ago · Kisqali is a prescription medicine that may be used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults: in combination with an aromatase inhibitor for stage II and …
Kisqali: What to Expect, Side Effects, and More - Breastcancer.org
Kisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
Kisqali: Dosage, Side Effects, Uses, and More - Healthline
Sep 13, 2023 · Kisqali (ribociclib) is a prescription drug that’s used to treat breast cancer. Kisqali comes as a tablet that you swallow. Kisqali is prescribed for adults to treat HR-positive and...
Kisqali (ribociclib) - Uses, Side Effects, and More - WebMD
Aug 26, 2024 · Kisqali (ribociclib) is commonly used for treating breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative and is advanced or has...
Metastatic Breast Cancer | KISQALI® (ribociclib)
Learn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
Kisqali: Cost, side effects, alternatives, dosage, and more
Dec 12, 2020 · Kisqali is indicated to treat advanced or metastatic breast cancer that’s hormone receptor-positive (HR-positive) and HER-2 negative. It’s approved for use: with an aromatase...
How Kisqali Works for Breast Cancer - WebMD
Kisqali (ribociclib) is a medicine used for certain types of breast cancer. Kisqali is used to treat breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
Sep 17, 2024 · Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with node-negative disease3-6.
Ribociclib (Kisqali®) - Macmillan Cancer Support
Ribociclib (Kisqali®) is used to treat breast cancer that is oestrogen-receptor positive and HER2 negative. It may be used if the cancer has spread: to the tissues and lymph nodes close to the breast (locally advanced), and surgery is not possible. from the breast to other parts of the body (metastatic or secondary breast cancer).